Search
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [suvorexant]) act to counteract inappropriate wakefulness.
Amoxapine
go.drugbank.com/drugs/DB00543ApprovedIn non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEtoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawn[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
Imdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigational[L23524] In November 2021, the same indication was approved by the EMA. … [A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalIt is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Second Degree Burns
go.drugbank.com/conditions/DBCOND0057796Synonyms: Blisters with epidermal loss due to burn (second degree), unspecified siteRaxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigationalIt works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Synonyms: RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptideImetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow